Sickle Cell Disease

Detailed Overview

SCD is the most common inherited blood disorder in the United States. The rigid, sickled red blood cells cause microvascular occlusion resulting in tissue ischemia and excruciating pain crises. Constant hemolysis leads to chronic anemia, jaundice, and gallstones. Over time, recurrent vaso-occlusion causes end-organ infarction, most notably autosplenectomy in childhood, rendering patients highly susceptible to encapsulated bacteria. Management focuses on preventing polymerization with Hydroxyurea, aggressive management of pain crises, and potentially curative hematopoietic stem cell transplantation or gene therapy.

Epidemiology & Demographics

Affects approximately 100,000 Americans, predominantly those of sub-Saharan African descent. Occurs in 1 out of every 365 Black or African American births. The sickle cell trait (HbAS) protects against severe Plasmodium falciparum malaria, driving its evolutionary preservation in endemic areas.

Etiological Mechanism

Caused by a single point mutation in the beta-globin gene (HBB) on chromosome 11, where glutamic acid is replaced by valine at the 6th position of the beta chain. Homozygosity (HbSS) causes Sickle Cell Anemia. Heterozygous compound states (HbSC, HbS-beta thalassemia) also cause the disease but with varying severities.

Primary Causes

Inheritance of two abnormal HBB genes (at least one being the HbS allele)

• African, Mediterranean, or Middle Eastern Descent: Populations with high historical exposure to malaria carry the gene mutation at much higher rates.
• Hypoxia, Dehydration, Acidosis: These physiological stressors act as direct triggers for acute sickle cell crises by promoting HbS polymerization.

Normal HbA remains soluble when deoxygenated. Mutant HbS, due to the hydrophobic valine substitution, undergoes conformational changes upon deoxygenation, exposing a sticky patch that binds to other HbS molecules. This forms long, rigid polymers that distort the RBC into a sickle shape. Initially reversible upon reoxygenation, repeated cycles damage the RBC membrane, leading to irreversible sickling. These rigid cells increase blood viscosity, damage the vascular endothelium, and mechanically obstruct post-capillary venules (Vaso-Occlusive Crisis). Furthermore, the damaged RBC membranes cause premature destruction by macrophages in the spleen (extravascular hemolysis) and direct intravascular lysis, liberating free hemoglobin which scavenges nitric oxide, causing systemic vasoconstriction and pulmonary hypertension.

Characteristic Clinical Presentation

• Acute Pain Crises (Vaso-Occlusive Crises): Sudden, agonizing pain in the back, chest, extremities, or abdomen lasting days to weeks.
• Fatigue and Weakness: Due to chronic, profound hemolytic anemia.
• Dactylitis: Painful swelling of the hands and feet; often the first presenting sign in infants.

Physical Examination Signs

• Scleral Icterus and Jaundice
• Splenomegaly (early) / Non-palpable Spleen (late)

• Acute Chest Syndrome (ACS): Vaso-occlusion in the pulmonary microvasculature leading to fever, chest pain, and hypoxia. Leading cause of death in adults.
• Stroke: Cerebral infarction common in children; detected early by Transcranial Doppler ultrasound.
• Functional Asplenia: Extreme susceptibility to overwhelming sepsis from encapsulated organisms (S. pneumoniae, N. meningitidis, H. influenzae).

Diagnostic Criteria & Guidelines

Universal newborn screening in the US via Isoelectric Focusing or High-Performance Liquid Chromatography (HPLC). Confirmed by Hemoglobin Electrophoresis showing absence of HbA, dominance of HbS (>85%), and variable HbF.

Differential Diagnosis

• Thalassemia Major
• Hemoglobin C Disease
• Hereditary Spherocytosis

Laboratory Tests & Biomarkers

• Hemoglobin Electrophoresis: HbS > 85%, HbA 0%, HbF 2-15%.
• Peripheral Blood Smear: Reveals irreversibly sickled cells, target cells, and Howell-Jolly bodies (indicating asplenia).
• Hemolysis Panel: Elevated indirect bilirubin, elevated LDH, decreased haptoglobin, and high reticulocyte count (10-20%).

Imaging Modalities & Findings

• Transcranial Doppler (TCD):
• Chest X-Ray:

• Infancy (Fetal Hb protective)
  Symptoms usually do not appear until ~6 months of age when fetal hemoglobin (HbF) levels drop.
• Chronic Disease State
  Characterized by recurrent VOCs, chronic pain, avascular necrosis of joints, and progressive renal/pulmonary failure.

Second-Line & Adjunctive Therapy

Disease Modifying: L-glutamine, Crizanlizumab (P-selectin inhibitor), or Voxelotor (HbS polymerization inhibitor). Curative: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for children with matched sibling donors. Emerging Gene Therapies (e.g., Exa-cel / Casgevy) using CRISPR to reactivate fetal hemoglobin.

Surgical & Procedural Management

Cholecystectomy for symptomatic pigment gallstones. Total hip arthroplasty for severe avascular necrosis of the femoral head.

Recommended Lifestyle Changes

• Avoid extreme temperatures (hot or cold).
• Maintain aggressive oral hydration (intravascular volume expansion prevents sickling).
• Avoid high altitudes and unpressurized aircraft.

Patient Counseling & Advice

Instruct parents of infants to seek immediate emergency care for ANY fever > 101.3F (38.5C) due to the risk of fatal pneumococcal sepsis. Educate on the importance of strict adherence to Hydroxyurea to prevent long-term organ damage.

Follow-Up & Monitoring Schedule

Comprehensive clinic visits every 3-6 months. Annual TCD until age 16. Annual screening for microalbuminuria, retinopathy (eye exam), and pulmonary hypertension (Echocardiogram).

Preventive Strategies

Genetic counseling for prospective parents with sickle cell trait. Prenatal diagnosis via chorionic villus sampling or amniocentesis.

Life expectancy has improved from 14 years (in 1970) to the mid-40s and 50s today. Major causes of mortality are Acute Chest Syndrome, sudden death from arrhythmias, and end-stage renal disease.